Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen (15) confirmed partial responses (PRs) have…
Endolith has reported a major advance in copper extraction as it pushes the frontiers of microbial science. In collaboration…
Just in time for Canada Crypto Week, Robinhood Markets (NASDAQ:HOOD) has announced a definitive agreement to acquire Canadian digital…
Sarama Resources (SRR:AU) has announced Q1 2025 Interim Financial Statements Download the PDF here. This post appeared first on…
Rare earths are important for many of today’s technologies and tomorrow’s carbon-free economy. Investors may not be very familiar…
Electric Royalties Ltd. (TSXV:ELEC)(OTCQB:ELECF) (‘Electric Royalties’ or the ‘Company’) notes that the recent export restrictions imposed by China on…
(TheNewswire) May 13, 2025 – TheNewswire – Vancouver, British Columbia, Canada JZR Gold Inc. (TSXV: JZR) (OTCQB: JZRIF) (the…
Sarama Resources (SRR:AU) has announced Q1 2025 Management’s Discussion and Analysis Download the PDF here. This post appeared first…